Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes.

Aims/hypothesis: The prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 1 diabetes remain unclear. Therefore, we investigated the prevalence and severity of MASLD in type 1 diabetes and assessed which clinical features are most important in predicting MASLD severity.

Methods: A total of 453 individuals with type 1 diabetes (41.